Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity - Trial NCT05304949
Access comprehensive clinical trial information for NCT05304949 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Pharmaceuticals and is currently Recruiting. The study focuses on Retinopathy of Prematurity. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Novartis Pharmaceuticals
Novartis
Timeline & Enrollment
N/A
Jun 22, 2022
Jan 12, 2025
Primary Outcome
Incidence of adverse events/adverse drug reactions
Summary
This study is an open-labeled, multicenter, single arm, observational post-marketing
 surveillance study under routine clinical practice with no mandated treatments, visits or
 assessments.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05304949
Non-Device Trial